Summary: David Sinclair's team, known for reversing aging through cell reprogramming, now shares new findings on a powerful NMN variant called MIB-626. The study, published in "The Journal of Clinical Endocrinology & Metabolism," explores MIB-626's effects on 30 participants, showing promising outcomes.
Background: NMN boosts NAD+ levels in the body, influencing various life processes. MIB-626, a more stable form of NMN, surpasses traditional NMN in performance.
Future Outlook: Apart from collaborating with the U.S. military, MIB-626 plans human trials for anti-aging, Alzheimer's, kidney issues, and ataxia.
Latest Results: In a 28-day trial with participants aged 45 and above, MIB-626 proved safe and effective:
- No severe side effects were reported.
- MIB-626 significantly increased NAD+ levels by 200%, impacting metabolism positively.
- Participants experienced weight loss, improved cholesterol levels, and reduced blood pressure.
Study Insights and Challenges: Despite positive outcomes, the study faced challenges such as a smaller participant count and a short trial duration. Age and other differences between groups raised concerns.
Upcoming Trials: Metro Biotech, focusing on MIB-626, has three ongoing trials, promising more insights.
Conclusion: While improvements are needed, the study's positive results highlight MIB-626's potential. Ongoing trials offer hope for a clearer understanding. The ultimate goal is the early launch of an anti-aging drug for broader public use.
